Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cyclerion Therapeutics (CYCN) Capital Expenditures (2019 - 2020)

Historic Capital Expenditures for Cyclerion Therapeutics (CYCN) over the last 2 years, with Q4 2020 value amounting to $35000.0.

  • Cyclerion Therapeutics' Capital Expenditures fell 7988.51% to $35000.0 in Q4 2020 from the same period last year, while for Dec 2022 it was $44000.0, marking a year-over-year decrease of 6302.52%. This contributed to the annual value of $7000.0 for FY2021, which is 9954.07% down from last year.
  • Cyclerion Therapeutics' Capital Expenditures amounted to $35000.0 in Q4 2020, which was down 7988.51% from $9000.0 recorded in Q3 2020.
  • In the past 5 years, Cyclerion Therapeutics' Capital Expenditures ranged from a high of $4.2 million in Q2 2019 and a low of $9000.0 during Q3 2020